InnoCan Pharma Corporation
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally. The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well… Read more
InnoCan Pharma Corporation (INNPF) - Net Assets
Latest net assets as of September 2025: $6.63 Million USD
Based on the latest financial reports, InnoCan Pharma Corporation (INNPF) has net assets worth $6.63 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.12 Million) and total liabilities ($4.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.63 Million |
| % of Total Assets | 59.66% |
| Annual Growth Rate | 17.15% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 375.98 |
InnoCan Pharma Corporation - Net Assets Trend (2015–2024)
This chart illustrates how InnoCan Pharma Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for InnoCan Pharma Corporation (2015–2024)
The table below shows the annual net assets of InnoCan Pharma Corporation from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $7.02 Million | +60.10% |
| 2023-12-31 | $4.39 Million | -29.54% |
| 2022-12-31 | $6.22 Million | -30.92% |
| 2021-12-31 | $9.01 Million | +349.82% |
| 2020-12-31 | $-3.61 Million | -355.27% |
| 2019-12-31 | $1.41 Million | +1012.60% |
| 2018-12-31 | $127.00K | -87.96% |
| 2017-12-31 | $1.05 Million | -20.97% |
| 2016-12-31 | $1.33 Million | -20.97% |
| 2015-12-31 | $1.69 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to InnoCan Pharma Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3429667100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $40.08 Million | 775.60% |
| Total Equity | $5.17 Million | 100.00% |
InnoCan Pharma Corporation Competitors by Market Cap
The table below lists competitors of InnoCan Pharma Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ON SEMICONDUCTOR
MU:XS4
|
$501.66K |
|
NO GRAVITY GAMES ZY -10
F:8YX
|
$502.85K |
|
Kmc Properties ASA
OL:KMCP
|
$502.99K |
|
FLEXTRONICS INTL - Dusseldorf Stock Exchang
DU:FXI
|
$503.11K |
|
TYSON FOODS -A- - Dusseldorf Stock Exchang
DU:TF7A
|
$501.17K |
|
Sentoria Group Bhd
KLSE:5213
|
$501.00K |
|
Ralco Agencies Ltd
TA:RLCO
|
$500.79K |
|
Panacea Life Sciences Holdings Inc
OTCQB:PLSH
|
$500.75K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InnoCan Pharma Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,103,000 to 5,167,000, a change of 1,064,000 (25.9%).
- Net loss of 1,834,000 reduced equity.
- New share issuances of 891,000 increased equity.
- Other factors increased equity by 2,007,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.83 Million | -35.49% |
| Share Issuances | $891.00K | +17.24% |
| Other Changes | $2.01 Million | +38.84% |
| Total Change | $- | 25.93% |
Book Value vs Market Value Analysis
This analysis compares InnoCan Pharma Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 2.38x to 0.11x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $0.06 | $0.14 | x |
| 2019-12-31 | $0.65 | $0.14 | x |
| 2020-12-31 | $-1.48 | $0.14 | x |
| 2021-12-31 | $2.69 | $0.14 | x |
| 2022-12-31 | $1.71 | $0.14 | x |
| 2023-12-31 | $1.06 | $0.14 | x |
| 2024-12-31 | $1.23 | $0.14 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InnoCan Pharma Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -35.49%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6.23%
- • Asset Turnover: 3.18x
- • Equity Multiplier: 1.79x
- Recent ROE (-35.49%) is above the historical average (-154.30%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 25.95% | 37.48% | 0.66x | 1.05x | $269.41K |
| 2016 | -45.28% | -94.01% | 0.43x | 1.13x | $-737.63K |
| 2017 | -29.23% | 0.00% | 0.00x | 1.37x | $-413.70K |
| 2018 | -938.58% | 0.00% | 0.00x | 5.20x | $-1.20 Million |
| 2019 | -236.02% | 0.00% | 0.00x | 1.83x | $-3.48 Million |
| 2020 | 0.00% | -124412.50% | 0.00x | 0.00x | $-9.59 Million |
| 2021 | -110.96% | -5126.02% | 0.02x | 1.39x | $-10.95 Million |
| 2022 | -58.87% | -147.09% | 0.37x | 1.09x | $-4.40 Million |
| 2023 | -114.55% | -34.41% | 1.97x | 1.69x | $-5.11 Million |
| 2024 | -35.49% | -6.23% | 3.18x | 1.79x | $-2.35 Million |
Industry Comparison
This section compares InnoCan Pharma Corporation's net assets metrics with peer companies in the Household & Personal Products industry.
Industry Context
- Industry: Household & Personal Products
- Average net assets among peers: $1,833,853,398
- Average return on equity (ROE) among peers: 27.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InnoCan Pharma Corporation (INNPF) | $6.63 Million | 25.95% | 0.68x | $501.28K |
| Acme United Corporation (ACU) | $19.90 Million | 2.51% | 0.55x | $132.86 Million |
| Beiersdorf Aktiengesellschaft (BDRFF) | $3.02 Billion | 8.59% | 0.75x | $11.93 Billion |
| Science to Consumers Inc (BEUT) | $-3.05K | 0.00% | 0.00x | $1.09K |
| Société BIC SA (BICEY) | $1.70 Billion | 16.88% | 0.41x | $566.61 Million |
| Blue Moon Group Holdings Limited (BLUMY) | $12.35 Billion | 8.22% | 0.18x | $1.01 Billion |
| Bemax Inc (BMXC) | $-244.86K | 0.00% | 0.00x | $3.63K |
| Bruush Oral Care Inc. (BRSHF) | $-216.93K | 0.00% | 0.00x | $335.48 |
| Park Ha Biological Technology Co., Ltd. (BYAH) | $-578.18K | 0.00% | 0.00x | $11.97 Million |
| Church & Dwight Company Inc (CHD) | $284.43 Million | 16.52% | 2.34x | $22.97 Billion |
| Colgate-Palmolive Company (CL) | $971.00 Million | 223.07% | 14.49x | $67.85 Billion |